{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:07:43Z","timestamp":1791929263434,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004086","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000}}],"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["CO-CIN-01"],"award-info":[{"award-number":["CO-CIN-01"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["Senior Investigator Award 201385"],"award-info":[{"award-number":["Senior Investigator Award 201385"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["Advanced Fellowship NIHR300669"],"award-info":[{"award-number":["Advanced Fellowship NIHR300669"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_19059"],"award-info":[{"award-number":["MC_PC_19059"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V028979\/1"],"award-info":[{"award-number":["MR\/V028979\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office, Scottish Government Health and Social Care Directorate","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215091\/Z\/18\/Z"],"award-info":[{"award-number":["215091\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["205228\/Z\/16\/Z"],"award-info":[{"award-number":["205228\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1209135"],"award-info":[{"award-number":["OPP1209135"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Liverpool Experimental Cancer Medicine Centre","award":["C18616\/A25153"],"award-info":[{"award-number":["C18616\/A25153"]}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["200907"],"award-info":[{"award-number":["200907"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["IS-BRC-1215-20013"],"award-info":[{"award-number":["IS-BRC-1215-20013"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PREPARE","award":["FP7 project 602525"],"award-info":[{"award-number":["FP7 project 602525"]}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"crossref","award":["MC_PC_20029"],"award-info":[{"award-number":["MC_PC_20029"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunocompromised patients may be at higher risk of mortality if hospitalised with Coronavirus Disease 2019 (COVID-19) compared with immunocompetent patients. However, previous studies have been contradictory. We aimed to determine whether immunocompromised patients were at greater risk of in-hospital death and how this risk changed over the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We included patients &gt; = 19 years with symptomatic community-acquired COVID-19 recruited to the ISARIC WHO Clinical Characterisation Protocol UK prospective cohort study. We defined immunocompromise as immunosuppressant medication preadmission, cancer treatment, organ transplant, HIV, or congenital immunodeficiency. We used logistic regression to compare the risk of death in both groups, adjusting for age, sex, deprivation, ethnicity, vaccination, and comorbidities. We used Bayesian logistic regression to explore mortality over time. Between 17 January 2020 and 28 February 2022, we recruited 156,552 eligible patients, of whom 21,954 (14%) were immunocompromised. In total, 29% (\n                      <jats:italic>n<\/jats:italic>\n                      = 6,499) of immunocompromised and 21% (\n                      <jats:italic>n<\/jats:italic>\n                      = 28,608) of immunocompetent patients died in hospital. The odds of in-hospital mortality were elevated for immunocompromised patients (adjusted OR 1.44, 95% CI [1.39, 1.50],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Not all immunocompromising conditions had the same risk, for example, patients on active cancer treatment were less likely to have their care escalated to intensive care (adjusted OR 0.77, 95% CI [0.7, 0.85],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) or ventilation (adjusted OR 0.65, 95% CI [0.56, 0.76],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). However, cancer patients were more likely to die (adjusted OR 2.0, 95% CI [1.87, 2.15],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Analyses were adjusted for age, sex, socioeconomic deprivation, comorbidities, and vaccination status. As the pandemic progressed, in-hospital mortality reduced more slowly for immunocompromised patients than for immunocompetent patients. This was particularly evident with increasing age: the probability of the reduction in hospital mortality being less for immunocompromised patients aged 50 to 69 years was 88% for men and 83% for women, and for those &gt;80 years was 99% for men and 98% for women. The study is limited by a lack of detailed drug data prior to admission, including steroid doses, meaning that we may have incorrectly categorised some immunocompromised patients as immunocompetent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immunocompromised patients remain at elevated risk of death from COVID-19. Targeted measures such as additional vaccine doses, monoclonal antibodies, and nonpharmaceutical preventive interventions should be continually encouraged for this patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN66726260\" xlink:type=\"simple\">ISRCTN 66726260<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004086","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:33:10Z","timestamp":1675171990000},"page":"e1004086","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":100,"title":["Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-1693","authenticated-orcid":true,"given":"Lance","family":"Turtle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-9581","authenticated-orcid":true,"given":"Mathew","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-9560","authenticated-orcid":true,"given":"Maaike","family":"Swets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark D.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0701-8364","authenticated-orcid":true,"given":"Stephen","family":"Aston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-9212","authenticated-orcid":true,"given":"Thushan I.","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley E.","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-2555","authenticated-orcid":true,"given":"Peter J. M.","family":"Openshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewen M.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ISARIC4C investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-793X","authenticated-orcid":true,"given":"J. Kenneth","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9700-0418","authenticated-orcid":true,"given":"Malcolm G.","family":"Semple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-420X","authenticated-orcid":true,"given":"Annemarie B.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"pmed.1004086.ref001","doi-asserted-by":"crossref","first-page":"m1985","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20\u2009133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","volume":"369","author":"AB Docherty","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"pmed.1004086.ref002","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/rccm.202008-3265OC","article-title":"Tissue-Specific Immunopathology in Fatal COVID-19","volume":"203","author":"DA Dorward","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"57","key":"pmed.1004086.ref003","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg9873","article-title":"Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19.","volume":"6","author":"RS Thwaites","year":"2021","journal-title":"Sci Immunol."},{"issue":"49","key":"pmed.1004086.ref004","doi-asserted-by":"crossref","first-page":"eabd7114","DOI":"10.1126\/sciimmunol.abd7114","article-title":"Comprehensive mapping of immune perturbations associated with severe COVID-19.","volume":"5","author":"L Kuri-Cervantes","year":"2020","journal-title":"Sci Immunol."},{"issue":"596","key":"pmed.1004086.ref005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8654","article-title":"High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages","volume":"13","author":"W Hoepel","year":"2021","journal-title":"Sci Transl Med"},{"issue":"8","key":"pmed.1004086.ref006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"P Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"pmed.1004086.ref007","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"AC Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1004086.ref008","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.","author":"PW Horby","year":"2022"},{"issue":"7","key":"pmed.1004086.ref009","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/ajt.15941","article-title":"COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.","volume":"20","author":"MR Pereira","year":"2020","journal-title":"Am J Transplant"},{"issue":"6","key":"pmed.1004086.ref010","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.kint.2020.10.004","article-title":"COVID-19 infection in kidney transplant recipients at the epicenter of pandemics","volume":"98","author":"Y Azzi","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"pmed.1004086.ref011","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/ajt.16424","article-title":"Is COVID-19 infection more severe in kidney transplant recipients?","volume":"21","author":"S Caillard","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"pmed.1004086.ref012","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14216","article-title":"Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States.","volume":"35","author":"AM Fisher","year":"2021","journal-title":"Clin Transplant."},{"issue":"11","key":"pmed.1004086.ref013","doi-asserted-by":"crossref","first-page":"e4124","DOI":"10.1093\/cid\/ciaa1488","article-title":"Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System.","volume":"73","author":"KM Andersen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pmed.1004086.ref014","article-title":"Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis","author":"M Gatti","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"pmed.1004086.ref015","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/ndt\/gfaa271","article-title":"Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey.","volume":"35","author":"S Ozturk","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"7821","key":"pmed.1004086.ref016","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"EJ Williamson","year":"2020","journal-title":"Nature"},{"issue":"24","key":"pmed.1004086.ref017","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1001\/jama.2021.9321","article-title":"Vaccinated but Not Protected\u2014Living Immunocompromised During the Pandemic","volume":"325","author":"L. Ryan","year":"2021","journal-title":"JAMA"},{"key":"pmed.1004086.ref018","article-title":"Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves","author":"OV Swann","year":"2022","journal-title":"Pediatr Res"},{"key":"pmed.1004086.ref019","doi-asserted-by":"crossref","first-page":"m3339","DOI":"10.1136\/bmj.m3339","article-title":"Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.","volume":"370","author":"SR Knight","year":"2020","journal-title":"BMJ"},{"issue":"10286","key":"pmed.1004086.ref020","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.","volume":"397","author":"VJ Hall","year":"2021","journal-title":"Lancet"},{"key":"pmed.1004086.ref021","article-title":"The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England.","author":"RS Paton","year":"2022","journal-title":"Sci Transl Med."},{"issue":"7","key":"pmed.1004086.ref022","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-2600(21)00175-2","article-title":"Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK","volume":"9","author":"AB Docherty","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"43","key":"pmed.1004086.ref023","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse.","volume":"4","author":"H Wickham","year":"2019","journal-title":"J Open Source Softw."},{"key":"pmed.1004086.ref024","article-title":"finalfit: Quickly Create Elegant Regression Results Tables and Plots when Modelling","author":"E Harrison","year":"2022","journal-title":"Version 1.0.53"},{"issue":"1","key":"pmed.1004086.ref025","first-page":"1","article-title":"brms: An R Package for Bayesian Multilevel Models Using Stan","volume":"80","author":"P-C B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"issue":"18","key":"pmed.1004086.ref026","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"JR Conway","year":"2017","journal-title":"Bioinformatics"},{"issue":"1","key":"pmed.1004086.ref027","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative","volume":"4","author":"KM Andersen","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"10332","key":"pmed.1004086.ref028","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.","volume":"399","author":"T Nyberg","year":"2022","journal-title":"Lancet"},{"key":"pmed.1004086.ref029","article-title":"Hospital admission for symptomatic COVID-19 and impact of vaccination: analysis of linked data from the Coronavirus Clinical Information Network and the National Immunisation Management Service.","author":"C Egan","year":"2022","journal-title":"Anaesthesia"},{"issue":"42","key":"pmed.1004086.ref030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.15585\/mmwr.mm7142a4","article-title":"Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance\u2014VISION Network, 10 States, December 2021-August 2022.","volume":"71","author":"A Britton","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004086.ref031","article-title":"Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis","author":"WS Hart","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"pmed.1004086.ref032","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509","article-title":"Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.","volume":"26","author":"F Campbell","year":"2021","journal-title":"Eurosurveillance"},{"issue":"7","key":"pmed.1004086.ref033","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"WT Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"pmed.1004086.ref034","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"A Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"pmed.1004086.ref035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients","volume":"386","author":"RL Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004086.ref036","first-page":"e068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","author":"Wong SY Lee ARYB","year":"2022","journal-title":"BMJ"},{"key":"pmed.1004086.ref037","article-title":"WHO\u2019s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed","author":"MY Wu","year":"2022","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004086","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:35:52Z","timestamp":1676381752000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004086","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.08.22278576","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}